Letters to the Editor  by BORGSTRÖM, L.
Letters to the Editor
RESPIRATORY MEDICINE (2001) 95, 534–536
Available online at http://www.idealibrary.com ondoi:10.1053/rmed.2001.1072Dear Editor
Equivalent therapeutic ratio, of
salbutamol given by Turbuhaler1
and Diskus1 (Respir Med 2000, 94:
574–577)
It was with mixed feelings that I read the article by
Arvidsson et al. in a recent issue (1). In their introduction,
the authors state that ‘. . . clinical studies have demonstrated
equivalent, or even improved ecacy of these two drugs
when delivered via pMDI as compared with Turbuhaler’.
The authors use five references to support their statement.
A closer look at these five references, however, shows that
they do not in any way support this statement.
If anything it should be the other way around. This could
possibly be due to carelessness as reference 1 is used in
another article (2) by the same group in a correct way.
Another example of carelessness is obvious in the reference
list. Reference 1 is given with incomplete author list and the
title is not correct. Also in reference 7, the title is not given
correctly, even though the article is from the same research
group.
In addition, contrary to that stated in the article a direct
comparision between lung deposition after inhalation via
Turbuhaler and Diskus has been performed and was
published before the article was submitted (3). In that
study it was shown that lung deposition for budesonide
Turbuhaler was 34?1% and for fluticasone Diskus it was
12?6% of the nominal metered dose. These data are in line
with separately published lung deposition data for Diskus,
16?6% (4) and Turbuhaler, 32% (5) Also in another study a
significantly higher lung deposition was observed for
Turbuhaler as compared with Diskus (6). This is readily
available information that should lead the ‘no-difference’
outcome to be interpreted with caution.
In the present study, the authors use a cumulative design
to compare two different inhalers with the same active drug.
They show a dose–response over the dosing interval but do
not find any difference between the dose–response curves for
the two inhalers. They interpret the absence of a difference as
the presence of a similarity, which, of course, is against basic
statistical common sense. In addition, we performed and
published, before the present study was submitted, a study
where we compared salbutamol Turbuhaler 50mg with
salbutamol Turbuhaler 100mg in a cumulative design (7).
In total, 400 and 800mg were given on the two study days. In
spite of the known two-fold difference in dose given, there
was no difference between the two cumulative dose–response
curves. This absence of a difference we of course did not
interpret as the presence of a similarity. It would have been
ridiculous to claim that 50 equalled 100!0954-6111/01/060534+03 $35?00/0Figure 1 is hard to interpret as the bold line is denoted by
squares for the first three points and with triangles for the
other three points. For the dotted line it is the other way
around. A mix-up of data? If the lines in the picture are
correct (leaving the denotation apart) then it is hard to
understand the numerical analysis as given in the Results
section. In addition, it can be questioned if it is correct to
connect the baseline value with the first point after drug
intake on a dose scale. The baseline point, being zero, lies
infinitely far off to the left on a logarithmic scale. A more
fair presentation would have been to correct the three dose–
response curves for differences in baseline before presenting
the information in the figure. It is also more correct to
analyse comparative device studies on the dose, rather than
the effect, scale. With the given equivalence limits on the
effect scale it would then also most probabaly have been
able to show that two consecutive doses from the same
device were equivalent to each other.
The authors state that devices should be compared on an
equal microgram dose basis, but this statement is not
supported by any reference. It is not obvious why an equal-
dose comparison would be scientifically more strict than for
instance an equal-number of inhalations comparison. A
possible scenario, in a cumulative dose response study, is
that in an arm where a higher microgram dose was used the
full effect of the given dose is not obtained. In any
comparisons between drug devices we are looking for
differences. If no significant difference can be shown this
could in the single case be due to that the devices were not
compared on equal microgram doses, or equal number of
inhalations. If a significant difference was shown it was a
significant difference.
Finally, the statement that ‘. . . Turbuhaler has been
suggested to give more peripheral deposition . . .’ is not
supported by any reference. In the two available scinti-
graphic studies where regional deposition of inhaled drug
was compared between Turbuhaler and pMDI, the one
study showed very similar regional deposition (8) while the
other one showed a more central (!) deposition when
the drug was inhaled via Turbuhaler as compared with
pMDI (9).
I look forward to a discussion on the matters raised.
L. BORGSTRo¨M
Scientific Advisor, AstraZeneca R&D, Lund,
Sweden and Associate Professor, Uppsala University,
Uppsala, Sweden
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119–127.Prof. Borgstro¨m argues that the initial dose of a b2-
agonist may influence the effects of a second dose, and thus
that the results of findings at the higher levels of the dose–
response curve may be more dicult to compare. Interest-
ingly, however, Astra’s documentation for the Turbuhaler1
is based on cumulative dose–response studies (2–5).
Futhermore, there is a massive published documentation
regarding the appropriateness of using cumulative dose–
response designs in bronchodilator studies. In addition to
these scientific arguments, it may however be even more
important to remember that asthma patients, in real life,
use multiple doses from an inhaler when they experience
worsening of asthma. Thus, cumulative dosing may very
well be appropriate when comparing the effects of different
inhaled drugs. Regardless of this, we found no difference in
the effects of salbutamol Turbuhaler1 or Diskus1 at the
lowest dose used (200mg). Also, a study performed in
Southampton, U.K., showed no clinically relevant differ-
ences in maximal bronchodilating effect when therapeutic
doses of salbutamol were given via Turbuhaler1 either as
two consecutive doses or as two divided doses separated by
different time intervals (6).
We were careful to compare the same microgram doses,
in contrast to some more recent publications evolved from
studies sponsored by AstraZeneca (7,8). We did this to
avoid any advantage for any of the used inhalers. Our
conclusion must be, however aggravating it may be for
Prof. Borgstro¨m, that there is no or little difference in the
effects of salbutamol given by either Turbuhaler1 or
Diskus1, in the types of patients we have included in the
present study.
Prof. Borgstro¨m had some additional comments. One of
these has been addressed in a recent erratum. Importantly,
it is not required to reference studies published only as
abstracts, as these have not been peer reviewed. It is
extensively argued that the Turbuhaler1 gives better
peripheral deposition than other devices, and in a publica-
tion by Thorson et al. at AstraZeneca, it is stated that ‘the
systemic availability of budesonide, calculated as a geo-
metric mean and expressed as percentage of the metered
dose, was 38% for Turbuhaler1 and 26% for p-MDI’ (9).
We are not stating that there is a greater peripheral to
central deposition, but rather a greater total peripheral lung
deposition, using the Turbuhaler1 device. This argument,
extensively used at scientific meeting and in marketing
situations, may however be untrue as described in Prof.
Borgstro¨m’s letter, thus arguing against any improved
therapeutic ratio of a drug given by Turbuhaler1 vs. any
other device.
Importantly, we have high respect for Prof. Borgstro¨m’s
competence in this field, but we feel that it also must be
important to consider clinical implications of studies
comparing different devices. ‘In vivo veritas’ as stated by
Prof. Borgstro¨m previously (10).
P. ARVIDSSON, M. PALMQVIST AND J. LO¨TVALL
Lung Pharmacology Group,
Sahlgrenska Hospital,
Gothenburg, Swedendoi:10.1053/rmed.2001.1073
Dear Editor
Response to Prof. Borgstro¨m re: paper
by Arvidsson et al. (Respir Med 2000;
94: 574–577)
We have received the letter by Prof. Borgstrom, employed
by AstraZeneca R&D in Lund, regarding our recently
published study comparing the effects of salbutamol given
either by the Turbuhaler1 or the Diskus1 device (1). Prof.
Borgstro¨m is bringing up a series of unrelated issues, but
the key question is whether it is appropriate to use a
cumulative doss–response design when comparing the
clinical effects of bronchodilators.
Briefly, our study compared the effects of salbutamol
given by two different inhalation devices, the Turbuhaler1
and the Diskus1. We found that there were no, or very
small, differences in the bronchodilating effects of salbuta-
mol given by either device, in a dose range of 200–3200 mg.
Importantly, we documented a clear dose–response rela-
tionship in FEV1 over this dose range (2?2–2?5 l), which is
important when comparing the potency of treatments.# 2001 HARCOURT PUBLISHERS LTD
